Effectiveness of triglycyl vasopressin in persistent hematuria associated with sickle cell hemoglobin.
Two cases of persistent hematuria associated with the presence of sickle cell hemoglobin were treated intravenously with triglycyl vasopressin, a drug not previously used for this condition. One patient, a 16-year-old boy, had hemoglobin AS. Both patients had a history of severe hematuria persisting over several months, resistant to the usual forms of therapy, and requiring numerous transfusions. In each patient, the condition responded to intravenous triglycyl vasopression therapy, with cessation of hematuria. Experimental studies in dogs indicate that triglycyl vasopressin reduces renal blood flow substantially. Further trial of triglycyl vasopressin in severe hematuria associated with the presence of sickle cell hemoglobin appears to be indicated.
D000293:Adolescent; D000328:Adult; D000755:Anemia, Sickle Cell / Q000175:diagnosis / Q000503:physiopathology / Q000652:urine*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D004285:Dogs; D004906:Erythrocyte Count; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006417:Hematuria / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D006451:Hemoglobin, Sickle / Q000032:analysis*; D006801:Humans; D008236:Lypressin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D011674:Pulse / Q000187:drug effects; D012039:Regional Blood Flow / Q000187:drug effects; D012077:Renal Artery / Q000187:drug effects; D000077585:Terlipressin
D006451:Hemoglobin, Sickle; D008236:Lypressin; D000077585:Terlipressin